This retrospective, case-control study aimed to identify variables associated with the incidence of Clostridium difficile-associated diarrhea (CDAD) in acute care facilities and to specifically identify the relationship of fluoroquinolones and acid suppressive agents in the development of CDAD. Seventy-one symptomatic patients positive for C. difficile toxin A or B hospitalized for at least 72 hours were compared with 142 control patients hospitalized for at least 72 hours who were not positive for C. difficile toxin A or B. Two controls were matched to one case patient for age within 5 years, unit of admission, and date of admission. The mean ages for cases and controls were 63.5 and 62.7 years, respectively. After adjusting for two confounding variables-hospital stay within 3 months and Charlson Comorbidity Index-conditional multiple logistic regression identified six risk factors for development of CDAD: gastrointestinal procedures within 60 days (odds ratio [OR] 9.1, P < 0.013), levofloxacin exposure (OR 8.2, P < 0.033), moxifloxacin exposure (OR 4.1, P < 0.026), imipenem exposure (OR 14.9, P < 0.014), laxative use (OR 20.2, P < 0.0001), and immunosuppressive use (OR 20.7, P < 0.034). The risk of CDAD after exposure to levofloxacin or moxifloxacin was not significantly different. Acid suppressive therapy was not a risk factor for CDAD development.
utbreaks of Clostridium diffi cile-associated diarrhea (CDAD) have been reported in acute care as well as long-term care facilities (1, 2) . Disruption of the normal gut fl ora allows colonization with C. diffi cile (3) . C. diffi cile colonization in adult patients may increase by 10% to 30% during hospitalization, but not all patients will develop disease. Known risk factors associated with CDAD development include prior exposure to antimicrobials, gastrointestinal (GI) surgery, feeding tubes, chemotherapy, environmental exposure, advanced age, severity of comorbid conditions, and GI stimulants, stool softeners, and enemas (1, 2, 4, 5) . Although the strongest evidence with antimicrobial exposure exists with clindamycin, penicillins, and cephalosporins (4-11), reports have implicated fl uoroquinolone use as a potential risk factor in the development of CDAD (2, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Proton pump inhibitors (PPIs) are another pharmacologic class suggested as a risk factor in the development of CDAD (21, 22) .
Hillcrest Medical Center is a licensed 557-bed tertiary care hospital located in northeast Oklahoma. Th is institution had experienced an apparent increase in CDAD cases over a 2-year period (years 2001-2003) with no defi ned cause, although a correlation with a formulary change from levofl oxacin to moxifl oxacin had been postulated. In addition, intravenous PPI therapy became available during this time period. Th e primary objective of this study was to evaluate the relationship of CDAD with levofl oxacin or moxifl oxacin use in acutely ill patients. Secondary study objectives included evaluating the relationship between CDAD and PPI use in acutely ill patients and describing the treatment regimens and outcomes of CDAD patients.
METHODS

Study design
Th is study was conducted in the general medical wards and intensive care units (ICUs) at Hillcrest Medical Center. A retrospective chart review was conducted in patients with CDAD or at risk for CDAD in acute care areas who were admitted between August 1, 2001 , and August 31, 2003. Levofl oxacin was the formulary fl uoroquinolone from August 2001 to June 2002, and moxifl oxacin was utilized from July 2002 to the end of the study analysis. Patients were excluded from participation if they were discharged from the hospital in <72 hours, were <18 or >89 years of age, had a previous CDAD diagnosis, showed symptoms within rather than after 72 hours of hospitalization, were treated in nonacute care areas, or did not have a chart available from medical records. Th is study was approved by the institutional review boards of the University of Oklahoma Health Sciences Center and Hillcrest Medical Center. Medical charts included in the study were identifi ed using microbiological data (identifi cation of C. diffi cile toxin A/B during the study period; Wompole™ C. Diff QuikChek Complete™, Inverness Medical, Princeton, NJ) and admission data.
A retrospective case-control study design was used. Cases included patients with acute onset of loose bowel movements persisting for ≥2 days who tested positive for C. diffi cile toxin A and/or toxin B. Th e date of positive toxin test was defi ned as the date of diagnosis. For each case patient with CDAD, two control patients were matched for age (within 5 years), unit of admission, and month of admission. Controls had to have a minimum length of stay of 3 days. Data from a single case of CDAD for each patient were included in the study analysis. Data collected included patient age, gender, race, the presence of comorbidities, alcohol abuse or current use of cigarettes as identifi ed in the social history, patient location at time of CDAD diagnosis, and diagnosis at admission. Th e following variables were documented and assessed as risk factors associated with exposure before the development of CDAD: recent hospital admission within the previous 90 days, admission to the ICU, length of hospital stay prior to CDAD diagnosis, total hospital length of stay, GI procedure or surgery within 60 days of illness or during admission, previous antimicrobial use (e.g., fl uoroquinolones, vancomycin, clindamycin, penicillins, cephalosporins, metronidazole), duration of antimicrobial treatment, other medications (chemotherapy, immunosuppressives, PPIs, histamine-2 receptor antagonists [H2RAs]), administration of enteral or parenteral nutrition, and presence of a nasogastric or nasotracheal tube. Data were recorded until the patient was discharged from the hospital, transferred to a long-term care facility, or died.
Statistical analysis
Statistical analysis was performed using SAS software, version 9.1 (SAS Institute, Cary, NC) (23) . Univariate analysis was performed separately for each of the variables. Variables with a P value of ≤0.2 in the univariate analysis were included in a conditional multiple logistic regression model, as were the indicator variables for prior exposure to moxifl oxacin and levofl oxacin since these were the primary variables of interest. A manual backward selection process was used. Risk factors were checked for confounding and colinearity. Confounders were included in multivariate models if covariate inclusion changed the coeffi cient of any statistically signifi cant variable in the logistic regression model by 10% or greater. Th e odds ratios for prior exposure to moxifl oxacin and levofl oxacin were evaluated using a Z test comparing parameter estimates. All tests were two tailed, and a P value of ≤0.05 was considered signifi cant in the multivariate model.
RESULTS
Based on microbiological data, 302 patients were identifi ed as positive for C. diffi cile toxin A or B during the study period. Of these patients, 46 were excluded for prior C. diffi cile infection, 26 patients were symptomatic within 72 hours of hospitalization, 102 patients were admitted to the rehabilitation or long-term care units, 27 patients did not meet the age requirements, and 30 patients were unable to be matched to the two required control patients. Data were collected and analyzed for 71 case and 142 control patients.
Only three patient characteristics were signifi cantly diff erent between the case and control groups: recent hospitalization, GI procedure in the last 60 days, and GI procedure in the hospital (Table 1) . Th e most commonly performed GI procedures for both groups included colonoscopy, exploratory laparotomy, esophagogastroduodenoscopy, and percutaneous endoscopic gastrostomy tube placement. Th e use of several types of medication was associated with CDAD, but PPIs and H2RAs were not among them (Table 2 ).
In the logistic regression model controlling for hospital stay within the previous 3 months and Charlson Comorbidity Index, six variables were found to increase the risk of CDAD (Table 3) . Th e risk of developing CDAD after moxifl oxacin or levofl oxacin exposure was not signifi cantly diff erent. Th e case patients who received levofl oxacin therapy received it primarily on an outpatient basis where a majority of patients who received moxifl oxacin were treated on an inpatient basis. Treatment of the CDAD episode for case patients included metronidazole therapy in 89% and withdrawal of the suspected causative agent in 11%. As shown in Table 4 , patients who developed CDAD had longer lengths of stay for both the ICU and total hospitalization. Mortality was similar in the case and control patients.
DISCUSSION
Our study suggests that there is an increased risk of CDAD after exposure to moxifl oxacin or levofl oxacin in patients who develop symptoms and test positive for C. diffi cile toxin A or B after 72 hours of admission to the hospital. No statistically signifi cant diff erence in risk of CDAD development was identifi ed between moxifl oxacin exposure and levofl oxacin exposure. Th e hypothesis that moxifl oxacin could increase CDAD rates as compared to levofl oxacin is due to its greater propensity to aff ect anaerobic organisms (24) . Several case reports and reviews have identifi ed this potential risk (25) . Our fi ndings are similar to a recent case-control study of outpatients that found comparable risks of hospitalization for CDAD with gatifl oxacin, moxifl oxacin, and levofl oxacin (26) . Two studies have also postulated an increase in CDAD related to a change in formulary fl uoroquinolone, although only one of these studies was able to control the outbreak by switching back to the original fl uoroquinolone (2, 27) . A large retrospective case-control study completed within the Veterans Administration (VA) documented that the increased CDAD rates observed were not associated with fl uoroquinolone formulary change to gatifl oxacin but with seasonal variation in CDAD rates (28) . Another case-control study in the VA system confi rmed that an increase in CDAD rates was not associated with the addition of gatifl oxacin to the formulary (29) . A prospective study of nosocomial CDAD in several Canadian institutions found an increased risk with ciprofl oxacin, levofl oxacin, and gatifl oxacin in a multivariate model (30) . Continuing research in this area suggests that fl uoroquinolones in general are risk factors for CDAD development (11, (31) (32) (33) . Th e eff ect of acid suppressive therapy on rates of CDAD has recently been debated (34) . In our study, no association was identifi ed between PPIs or H2RAs and increased risk of CDAD. An explanation for this in our study may be the low number of patients using these agents in the outpatient setting and the possibility that increased risk may be related to prolonged use. Several other studies have found no link between acid suppressive therapy and CDAD, including a VA study (28) , a recent case-control trial of community-dwelling outpatients (35), a study of hospitalized patients (32) , and a prospective study in several institutions in Canada (30) . In contrast, a large community-based case-control trial found that the use of acid suppressants, especially PPIs, as well as nonsteroidal anti-infl ammatory agents was associated with an increased risk for development of CDAD (36) , and a retrospective case-control study in Kansas identifi ed an increased risk of CDAD with exposure to PPI therapy (37) . In all, the data remain inconclusive but confi rm that PPIs should be screened for inappropriate use and discontinued in those situations to avoid potential adverse sequelae (38) . An interesting fi nding in our study was the increased risk of CDAD after GI procedures completed within the previous 60 days. Th e ability to associate the development of CDAD with the procedure itself versus the agents used prior to the procedures (i.e., electrolyte preparation solutions or topical antimicrobial agents) is limited by the lack of outpatient information. A proportion of patients in this study also underwent inpatient GI procedures, raising the question of whether these patients had infl ammatory bowel disease that was previously undiagnosed and not captured due to study design. In prior studies, there appears to be a link with preexisting intestinal conditions or procedures and CDAD development (28, 39) . Th e increased risk of CDAD with laxative exposure is not a new fi nding (4) .
Th e increased risk of CDAD with imipenem/cilastatin found in our study is supported by evidence from other trials in patients with immunosuppression. A signifi cant increase in CDAD occurred with imipenem/cilastatin compared with clinafl oxacin for empiric treatment of febrile neutropenia (40) . A similar fi nding of increased CDAD in neutropenic patients was found with imipenem and vancomycin compared with cefoperazone-sulbactam and vancomycin therapy for suspected or documented infections (41) . Compared with ceftazidime, use of imipenem in febrile neutropenic patients was associated with greater gastrointestinal toxicity, including CDAD and nausea and vomiting (42) . A recent case-control study of CDAD in hospitalized patients also identifi ed that imipenem/cilastatin was associated with increased rates of CDAD (43) .
Th e identifi cation of those patients most at risk for CDAD is paramount in the prevention and treatment of this disease. Scoring models for CDAD have been developed to identify those patients who may be at risk (44, 45) . Th e Waterlow score, used for identifying the risk of developing pressure ulcers, has also been linked to the risk of CDAD (44) . Also utilized is the clinical risk scoring model, which has four variables (age, hemodialysis, surgical admission status, and ICU length of stay) and identifi es those patients at risk for CDAD (45) . Th ese scoring models, when used appropriately, may help guide physicians when prescribing broad-spectrum antimicrobial therapy, ordering GI procedures, and implementing preventative CDAD procedures.
Due to the design of this study, several major limitations must be addressed. Th is review was conducted at a single institution. Our study focused on patients who may have acquired CDAD after hospitalization in an eff ort to capture inpatient exposures to medications or other risk factors, which limits the ability to generalize these results to other patient populations. Due to the retrospective nature of the study, the agents selected for treatment for the initial suspected infection or CDAD could not be controlled. In addition, the complete duration of therapy of the various antimicrobial, immunosuppressive, laxative, and acid-reducing agents could not be specifi ed with the current design, as only the inpatient duration could be captured. While patients with CDAD receive isolation control including handwashing, gowning, and gloving as standard procedures in this institution, these variables are not routinely documented in the chart once isolation procedures are ordered. Another limitation to the study is the small number of patients who received moxifl oxacin and levofl oxacin during the study period, thus limiting the power of the study. Th is reduction in power may have resulted in the inability to fi nd a signifi cant diff erence between fl uoroquinolone exposures. Th e number of potential patients was greatly reduced by excluding patients who were symptomatic within the initial 72 hours of hospitalization or who had previous CDAD and the inability to match case patients with controls meeting the specifi ed criteria. Th e strains of C. diffi cile were not sent for epidemiologic typing to identify outbreak isolates, nor was antibiotic susceptibility testing completed for any of the isolates. Th is study is also limited because there could have been some changes in practice or diff erences in risk of CDAD due to other factors (seasonal or random differences in outbreaks) that could not be controlled.
In conclusion, in patients with CDAD identifi ed after at least 72 hours of hospitalization, an increased risk is present after exposure to levofl oxacin, moxifl oxacin, imipenem/cilastatin, laxative use, immunosuppressive use, and GI procedures within the previous 60 days. Th e risk of CDAD exposure was not signifi cantly diff erent between moxifl oxacin or levofl oxacin exposure. Exposure to PPIs or H2RAs did not increase the risk of CDAD development.
